Drugs / SYH2062
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06842537 | Mar → Dec 2025 overdue | — | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYH2062 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2062 INJECTION FOR THE TREATMENT OF ADULT ESSENTIAL HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA irasia.com ↗ |
| 2024-12-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYH2062 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH2062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06842537 ↗ |
| Route | Subcutaneous | “SYH2062 for sc injection” NCT06842537 ↗ |